Skip to main content

Advertisement

SpringerLink
Log in

Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update

  • Invited Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Over the last two decades, molecular-targeted agents have become mainstream treatment for many types of malignancies and have improved the overall survival of patients. However, most patients eventually develop resistance to these targeted therapies. Recently, immunotherapies such as immune checkpoint inhibitors have revolutionized the treatment paradigm for many types of malignancies. Immune checkpoint inhibitors have been approved for treatment of melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, Hodgkin’s lymphoma, bladder cancer and gastric cancer. However, oncologists have been faced with immune-related adverse events caused by immune checkpoint inhibitors; these are generally mild but can be fatal in some cases. Because immune checkpoint inhibitors have distinct toxicity profiles from those of chemotherapy or targeted therapy, many oncologists are not familiar with the principles for optimal management of immune-related adverse events, which require early recognition and appropriate treatment without delay. To achieve this, oncologists must educate patients and health-care workers, develop checklists of appropriate tests for immune-related adverse events and collaborate closely with organ specialists. Clinical questions that remain include whether immune checkpoint inhibitors should be administered to patients with autoimmune disease and whether patients for whom immune-related adverse events lead to delays in immunotherapy should be retreated. In addition, the predicted use of combination immunotherapies in the near future means that oncologists will face a higher incidence and severity of immune-related adverse events. This review provides an overview of the optimal management of immune-related adverse events attributed to immune checkpoint inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480:480–489

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330

    Article  PubMed  CAS  Google Scholar 

  4. Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23–34

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Carbone DP, Reck M, Paz-Ares L et al (2017) First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376(25):2415–2426

    Article  PubMed  CAS  Google Scholar 

  8. Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833

    Article  PubMed  CAS  Google Scholar 

  9. Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265

    Article  PubMed  Google Scholar 

  10. Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Younes A, Santoro A, Shipp M et al (2016) Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17:1283–1294

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909–1920

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10111):2461–2471

    Article  PubMed  CAS  Google Scholar 

  16. Wolchok JD, Saenger Y (2008) The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13:2–9

    Article  PubMed  CAS  Google Scholar 

  17. Minkis K, Garden BC, Wu S et al (2013) The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 69(3):e121–e128

    Article  PubMed  CAS  Google Scholar 

  18. Abdel-Rahman O, El Halawani H, Fouad M (2015) Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol 11:2471–2484

    Article  PubMed  CAS  Google Scholar 

  19. Cheng R, Cooper A, Kench J et al (2015) Ipilimumab-induced toxicities and the gastroenterologist. J Gastroenterol Hepatol 30(4):657–666

    Article  PubMed  CAS  Google Scholar 

  20. Di Giacomo AM, Danielli R, Guidoboni M et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58(8):1297–1306

    Article  PubMed  CAS  Google Scholar 

  21. Gentile NM, D’Souza A, Fujii LL et al (2013) Association between ipilimumab and celiac disease. Mayo Clin Proc 88(4):414–417

    Article  PubMed  CAS  Google Scholar 

  22. Ryder M, Callahan M, Postow MA et al (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 21(2):371–381

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Albarel F, Gaudy C, Castinetti F et al (2015) Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 172(2):195–204

    Article  PubMed  CAS  Google Scholar 

  24. Gaudy C, Clévy C, Monestier S et al (2015) Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care 38(11):e182–e183

    Article  PubMed  Google Scholar 

  25. Barjaktarevic IZ, Qadir N, Suri A et al (2013) Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. Chest 143(3):858–861

    Article  PubMed  Google Scholar 

  26. Berthod G, Lazor R, Letovanec I et al (2012) Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol 30(17):e156–e159

    Article  PubMed  Google Scholar 

  27. Thaipisuttikul I, Chapman P, Avila EK (2015) Peripheral neuropathy associated with ipilimumab: a report of 2 cases. J Immunother 38(2):77–79

    Article  PubMed  PubMed Central  Google Scholar 

  28. Gaudy-Marqueste C, Monestier S, Franques J et al (2013) A severe case of ipilimumab-induced Guillain–Barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother 36(1):77–78

    Article  PubMed  Google Scholar 

  29. Loochtan AI, Nickolich MS, Hobson-Webb LD (2015) Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. Muscle Nerve 52(2):307–308

    Article  PubMed  Google Scholar 

  30. Bernardo SG, Moskalenko M, Pan M et al (2013) Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res 23(1):47–54

    Article  PubMed  CAS  Google Scholar 

  31. Kleiner DE, Berman D (2012) Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 57(8):2233–2240

    Article  PubMed  PubMed Central  Google Scholar 

  32. Voskens C, Cavallaro A, Erdmann M et al (2012) Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. J Clin Oncol 30(33):e356–e357

    Article  PubMed  Google Scholar 

  33. Fadel F, Karoui EIK, Knebelmann B (2009) Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361(2):211–212

    Article  PubMed  CAS  Google Scholar 

  34. Izzedine H, Gueutin V, Gharbi C et al (2014) Kidney injuries related to ipilimumab. Invest New Drugs 32(4):769–773

    Article  PubMed  CAS  Google Scholar 

  35. Ahmad S, Lewis M, Corrie P et al (2012) Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma. J Oncol Pharm Pract 18(2):287–292

    Article  PubMed  CAS  Google Scholar 

  36. Akhtari M, Waller EK, Jaye DL et al (2009) Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 32(3):322–324

    Article  PubMed  Google Scholar 

  37. Du Rusquec P, Saint-Jean M, Brocard A et al (2014) Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma. J Immunother 37(6):348–350

    Article  PubMed  Google Scholar 

  38. Chan MMK, Kefford RF, Carlino M et al (2015) Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother 38(1):37–39

    Article  PubMed  CAS  Google Scholar 

  39. Hunter G, Voll C, Robinson CA (2009) Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci 36(4):518–520

    Article  PubMed  Google Scholar 

  40. Läubli H, Balmelli C, Bossard M et al (2015) Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer 3(1):11

    Article  PubMed  PubMed Central  Google Scholar 

  41. Geisler BP, Raad RA, Esaian D et al (2015) Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer 3(1):4

    Article  PubMed  PubMed Central  Google Scholar 

  42. Miserocchi E, Cimminiello C, Mazzola M et al (2015) New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient. Can J Ophthalmol 50(1):e2–e4

    Article  PubMed  Google Scholar 

  43. Weber JS, Hodi FS, Wolchok JD et al (2017) Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35(7):785–792

    Article  PubMed  CAS  Google Scholar 

  44. Khunger M, Rakshit S, Pasupuleti V et al (2017) Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 152(2):271–281

    Article  PubMed  Google Scholar 

  45. Pillai RN, Behera M, Owonikoko TK et al (2018) Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer 124(2):271–277

    Article  PubMed  CAS  Google Scholar 

  46. Wolchok JD, Neyns B, Linette G et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155–164

    Article  PubMed  CAS  Google Scholar 

  47. Phan GQ, Yang JC, Sherry RM et al (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100:8372–8377

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Freeman-Keller M, Kim Y, Cronin H et al (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(4):886–894

    Article  PubMed  CAS  Google Scholar 

  49. Champiat S, Lambotte O, Barreau E et al (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27(4):559–574

    Article  PubMed  CAS  Google Scholar 

  50. Bristol-Meyers Squibb: Yervoy (ipilimumab): Immune-mediated adverse reaction management guide. http://www.hcp.yervoy.com/servlet/servlet.FileDownload?file=00Pi000000PI1ZVEA1. Accessed 6 Mar 2018

  51. Horvat TZ, Adel NG, Dang T-O et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 33(28):3193–3198

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Weber JS, Kähler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21):2691–2697

    Article  PubMed  CAS  Google Scholar 

  53. Weber JS, Dummer R, de Pril V et al (2013) Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119(9):1675–1682

    Article  PubMed  CAS  Google Scholar 

  54. Kronbichler A, Jayne DRW, Mayer G (2015) Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest 45(3):346–368

    Article  PubMed  CAS  Google Scholar 

  55. Pedersen M, Andersen R, Nørgaard P et al (2014) Successful treatment with ipilimumab and interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother 63(12):1341–1346

    Article  PubMed  CAS  Google Scholar 

  56. Kyi C, Carvajal RD, Wolchok JD et al (2014) Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer 2(1):35

    Article  PubMed  PubMed Central  Google Scholar 

  57. Bostwick AD, Salama AK, Hanks BA (2015) Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer 3:19

    Article  PubMed  PubMed Central  Google Scholar 

  58. Weinstock C, Singh H, Maher VE et al (2017) FDA analysis of patients with baseline autoimmune diseases treated with PD-1/PD-L1 immunotherapy agents. J Clin Oncol. https://doi.org/10.1200/JCO.2017.35.15_suppl.3018

  59. Leonardi GC, Gainor JF, Azimi RS et al (2017) Use of PD-1 pathway inhibitors among patients with non-small cell lung cancer (NSCLC) and preexisting autoimmune disorders. J Clin Oncol. https://doi.org/10.1200/JCO.2017.35.15_suppl.9081

  60. Danlos FX, Voisin AL, Dyevre V et al (2018) Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 91:21–29

    Article  PubMed  CAS  Google Scholar 

  61. Santini FC, Rizvi H, Wilkins O et al (2017) Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy. J Clin Oncol. https://doi.org/10.1200/JCO.2017.35.15_suppl.9012

  62. Pollack MH, Betof A, Dearden H et al (2018) Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 29(1):250–255

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, Kyoto, 606-8507, Japan

    Hiroki Nagai & Manabu Muto

Authors
  1. Hiroki Nagai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manabu Muto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroki Nagai.

Ethics declarations

Conflict of interest

None of the authors of this study declared conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nagai, H., Muto, M. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. Int J Clin Oncol 23, 410–420 (2018). https://doi.org/10.1007/s10147-018-1259-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-018-1259-6

Keywords

Search

Navigation